Recent Updates
Recently added Catalysts
NKTR

Nektar to Webcast Presentation at Jefferies 2017 Global Healthcare Conference in New York City Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Jefferies 2017 Global Healthcare...

Key Takeaway: SAN FRANCISCO , June 6, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that its corporate presentation will be webcast at the upcoming Jefferies 2017 Global Healthcare Conference in New York City on Wednesday, June 7, 2017 at 9:30 a.m. Eastern time . Th

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+186%
120-day peak, hindsight
Typical move
10.2%
average across 4 past catalysts
Cash runway
~40 mo
Minimal dilution risk
Lead asset
Rezpegaldesleukin
Phase 3 · Moderate-to-Severe Atopic Dermatitis

Full Press Release Details

SAN FRANCISCO , June 6, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that its corporate presentation will be webcast at the upcoming Jefferies 2017 Global Healthcare Conference in New York City on Wednesday, June 7, 2017 at 9:30 a.m. Eastern time .
The presentation will be accessible via a Webcast through a link posted on the Investors, Events Calendar section of the Nektar website: http://ir.nektar.com/events.cfm . This Webcast will be available for replay until July 10, 2017 .
Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California , with additional operations in Huntsville, Alabama and Hyderabad, India . Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com .
Last updated: Jun 6, 2017